Entest BioMedical (OTCBB: ENTB) makes a Move after acquisition

Research Home

Search & Social

Deal Flow Media

Client Links

Stock Info

IR Web Report

Word Cloud

Friday

Jan212011

Entest BioMedical (OTCBB: ENTB) closed today at $3.50 and the stock was traded below $1.50 before the end of 2010. So what happened?

View the full ENTB chart at Wikinvest

Entest announced the acquisition of the McDonald Animal Hospital (MAH) in Santa Barbara, California. Entest officially took control of MAH on January 4, 2011. The McDonald Animal Hospital represents the first of several anticipated acquisitions by ENTB, and they are focusing on veterinary acquisition candidates in California. Thus, Entest has successfully completed its first move from a “emerging growth company” to a revenue producing business with significant upside potential from ImenVax™, which is the company's immuno-therapeutic cancer vaccine that utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. ImenVax was outlined in our ENTB Report @ Waterville Research. ENTB stated in their recent 8-K filing that they:

“currently plan to raise additional funds by obtaining governmental and non-governmental grants as well as offering securities for cash.”

This can often cause concerns for investors, but people are starting to see that David Koos and his management team are delivering results with limited capital on hand. Assuming the Company has capital, ENTB should be in a stronger position.

After our comparison of ENTB versus WOOF, VCA Antech (WOOF) has traded down the past few days despite a strong overall market. We will continue to post updates on ENTB.

Friday, January 21, 2011 at 8:53PM |

Email Article

Print Article

tagged

david koos,

entb,

entest,

mcdonald animal

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

All HTML will be escaped. Hyperlinks will be created for URLs automatically.

Copyright © 2002 - 2011 Waterville Investment Research. All rights Reserved. Waterville Investment Research, and affiliates (WR), publishe reports providing information on selected companies. WR is not a registered investment advisor or broker-dealer. These reports are provided as an information service only, and the statements and opinions in these reports should not be construed as an offer or solicitation to buy or sell any security. WR accepts no liability for any loss arising from an investor's reliance on or use of these reports. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. WR or an affiliate of WR has been/will be or may be compensated in Rule 144 stock of the Company for the publication and circulation of these reports. The maximum amount charged by WR is $75,000 in Rule 144 stock per report. WR intends to sell all or a portion of the of the Rule 144 stock in accordance with all securities laws, which prevents WR from selling stock for a period of six months to one year depending on the Bulletin Board and Pink Sheets regulations. WR, as a matter of internal policy, will not buy or sell shares of Company(s) stock in the open market. These reports contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of the individual Companies including the company's most recent annual and quarterly reports.